share_log

三葉草生物-B：截至2023年12月31日止年度全年業績公告及建議修訂組織章程大綱及章程細則

CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

香港交易所 ·  Mar 26 18:08
Summary by Moomoo AI
三葉草生物-B（股份代號：2197）公佈截至2023年12月31日止年度全年業績，並建議修訂組織章程大綱及章程細則。集團年內虧損由2022年的人民幣24.52億元減少至人民幣1.39億元，收入為人民幣3925.5萬元，主要來自SCB-2019（CpG 1018╱鋁佐劑）及四價季節性流感疫苗在中國的商業銷售。其他收入及收益大幅增加，主要由於從CEPI收到的資金。研發開支及行政開支均顯著下降。現金及銀行結餘由2022年的人民幣18.57億元減少至人民幣10.95億元。集團在疫苗開發及業務營運方面取得進展，包括RSV疫苗進入臨床試驗階段，並與國光生物科技達成在中國大陸分銷四價季節性流感疫苗的獨家協議。集團亦於報告期內獲納入恒生創新藥指數。
三葉草生物-B（股份代號：2197）公佈截至2023年12月31日止年度全年業績，並建議修訂組織章程大綱及章程細則。集團年內虧損由2022年的人民幣24.52億元減少至人民幣1.39億元，收入為人民幣3925.5萬元，主要來自SCB-2019（CpG 1018╱鋁佐劑）及四價季節性流感疫苗在中國的商業銷售。其他收入及收益大幅增加，主要由於從CEPI收到的資金。研發開支及行政開支均顯著下降。現金及銀行結餘由2022年的人民幣18.57億元減少至人民幣10.95億元。集團在疫苗開發及業務營運方面取得進展，包括RSV疫苗進入臨床試驗階段，並與國光生物科技達成在中國大陸分銷四價季節性流感疫苗的獨家協議。集團亦於報告期內獲納入恒生創新藥指數。
CLOVER BIO-B (STOCK CODE: 2197) ANNOUNCES ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSES TO REVISE THE ORGANIZATION'S ARTICLES OF ASSOCIATION AND ARTICLES OF ASSOCIATION. The Group's loss for the year decreased from RMB24.52 billion in 2022 to RMB1.39 billion and revenue was RMB3925.5 million, mainly from commercial sales in China of SCB-2019 (CpG 1018/ aluminum additives) and four-price seasonal influenza vaccines. Other income and income increased significantly, mainly due to funds received from CEPI. R&D spending and administrative expenses both fell significantly. Cash and bank balances decreased from RMB18.57 billion in 2022 to RMB10.95 billion. The Group has made progress in vaccine development and business operations, including RSV vaccine entering the clinical trial phase and reaching an exclusive agreement with Guokowang Biotechnology to distribute four-price seasonal influenza vaccines in mainland China. The Group was also included in the Hang Seng Innovative Medicines Index during the reporting period.
CLOVER BIO-B (STOCK CODE: 2197) ANNOUNCES ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSES TO REVISE THE ORGANIZATION'S ARTICLES OF ASSOCIATION AND ARTICLES OF ASSOCIATION. The Group's loss for the year decreased from RMB24.52 billion in 2022 to RMB1.39 billion and revenue was RMB3925.5 million, mainly from commercial sales in China of SCB-2019 (CpG 1018/ aluminum additives) and four-price seasonal influenza vaccines. Other income and income increased significantly, mainly due to funds received from CEPI. R&D spending and administrative expenses both fell significantly. Cash and bank balances decreased from RMB18.57 billion in 2022 to RMB10.95 billion. The Group has made progress in vaccine development and business operations, including RSV vaccine entering the clinical trial phase and reaching an exclusive agreement with Guokowang Biotechnology to distribute four-price seasonal influenza vaccines in mainland China. The Group was also included in the Hang Seng Innovative Medicines Index during the reporting period.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more